Anavex Life Sciences Stock Quote AVXL - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

5.52

Bid

5.51

Ask

5.53

Volume

94,276

5.4021 Day's Range 5.56

3.25 52 Week Range 10.45

Market Cap

468.071M

Previous Close

5.49

Open

5.53

Last Trade

5.51

Last Trade Time

11:59:52

Financial Volume

$ 517,365

VWAP

5.4878

Average Volume (3m)

950,028

Shares Outstanding

84,795,517

Dividend Yield

PE Ratio

-9.75

Earnings Per Share (EPS)

-0.56

Revenue

Net Profit

-47.51M

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are u... Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.anavex.com

Headquarters

Carson City, Nevada, USA

Founded

Anavex Life Sciences Corporation is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker AVXL. The last closing price for Anavex Life Sciences was $5.49. Over the last year, Anavex Life Sciences shares have traded in a share price range of $ 3.25 to $ 10.45.

Anavex Life Sciences currently has 84,795,517 shares outstanding. The market capitalization of Anavex Life Sciences is $465.53 million. Anavex Life Sciences has a price to earnings ratio (PE ratio) of -9.75.

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...

Form 8-K - Current report

Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference

ANAVEX®2-73 corrects directly to humans’ translatable EEG biomarkers in a model of Fragile X Syndrome (FXS) Therapeutic potential to address behavioral and cognitive deficits in individuals with...

Form S-3 - Registration statement under Securities Act of 1933

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference

Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events...

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.1031	-1.83350820722	5.6231	5.935	5.28	1028640	5.58569654	CS
4	-0.78	-12.380952381	6.3	6.35	4.9301	796348	5.5112385	CS
12	1.42	34.6341463415	4.1	7.49	4	950028	5.96670453	CS
26	0.86	18.4549356223	4.66	7.49	3.25	1084960	4.84002946	CS
52	-1.33	-19.4160583942	6.85	10.45	3.25	1181767	5.6626757	CS
156	-13.64	-71.1899791232	19.16	23.73	3.25	1143344	9.17951624	CS
260	1.92	53.3333333333	3.6	31.5	2.2	1291102	10.43466193	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BNZIBanzai International Inc	$ 8.801 (109.55%)	44.73M
SEELSeelos Therapeutics Inc	$ 0.3811 (100.58%)	281.79M
MSSMaison Solutions Inc	$ 1.41 (97.20%)	76.53M
XHGXChange TED Inc	$ 1.04 (67.88%)	19.71M
WVEWave Life Sciences Ltd	$ 7.9191 (48.30%)	9.07M
BIVIBioVie Inc	$ 1.26 (-55.00%)	1.62M
GHSIGuardion Health Sciences Inc	$ 6.4561 (-38.63%)	278.2k
XPONExpion360 Inc	$ 0.0893 (-23.68%)	30.76M
FIACUFocus Impact Acquisition Corporation	$ 9.10 (-21.21%)	99
OTRKOntrak Inc	$ 2.70 (-19.40%)	96.35k
SEELSeelos Therapeutics Inc	$ 0.3811 (100.58%)	281.79M
NVDANVIDIA Corporation	$ 120.965 (4.05%)	144.12M
MLGOMicroAlgo Inc	$ 0.2208 (11.29%)	77.21M
MSSMaison Solutions Inc	$ 1.41 (97.20%)	76.53M
SQQQProShares UltraPro Short QQQ	$ 7.6199 (-1.93%)	75.43M